Earnings

bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate

Aug 7, 2026 · 08:11 AM ET· updated 1h ago

bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(2.40) by 73.33 percent. This is a 87.45 percent increase over losses of $(5.10) per

Why It Matters

bioAffinity lost less money than people expected, and also made more sales than predicted. This suggests the company is moving in a better direction, even though it's still losing money overall.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BIAF0.52

-0.01 (-1.83%)

MMM181.34

+0.63 (+0.35%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.